These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 2186415)

  • 1. Therapeutic target for cognition enhancers: diagnosis and clinical phenomenology.
    Allain H; Boyer P; Kossmann L; Lépine JP; Kanowski S
    Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():49-51. PubMed ID: 2186412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men.
    Lu PH; Masterman DA; Mulnard R; Cotman C; Miller B; Yaffe K; Reback E; Porter V; Swerdloff R; Cummings JL
    Arch Neurol; 2006 Feb; 63(2):177-85. PubMed ID: 16344336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
    Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
    Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A neuropsychological test battery for use in Alzheimer disease clinical trials.
    Harrison J; Minassian SL; Jenkins L; Black RS; Koller M; Grundman M
    Arch Neurol; 2007 Sep; 64(9):1323-9. PubMed ID: 17846273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
    Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early clinical testing of cognition enhancers: prediction of efficacy.
    Hall ST; Puech A; Schaffler K; Wesnes K; Gamzu ER
    Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():57-8; discussion 59. PubMed ID: 2186414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N; Ott BR; Peskind E; Resnick EM
    Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
    Filip V; Kolibás E
    J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early human trials in the assessment of cognition activators.
    Gamzu ER; Birkhimer LJ; Hoover T; Gracon ST
    Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():44-8. PubMed ID: 2186411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Problems in the search for cognition enhancers.
    Hollister LE
    Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():33-6. PubMed ID: 2186410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical issues of cognitive enhancers in Alzheimer disease.
    Calvani M; Carta A
    Alzheimer Dis Assoc Disord; 1991; 5 Suppl 1():S25-31. PubMed ID: 1781971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which treatments are effective for cognitive, behavioural and psychological symptoms in dementia?
    Warner JP; Butler R; Prabhakaran P
    Evid Based Ment Health; 2003 Aug; 6(3):69-71. PubMed ID: 12893782
    [No Abstract]   [Full Text] [Related]  

  • 17. Pragmatic Trials and Repurposed Drugs for Alzheimer Disease.
    Schneider LS
    JAMA Neurol; 2020 Feb; 77(2):162-163. PubMed ID: 31738375
    [No Abstract]   [Full Text] [Related]  

  • 18. Cognition enhancers in age-related cognitive decline.
    Riedel WJ; Jolles J
    Drugs Aging; 1996 Apr; 8(4):245-74. PubMed ID: 8920174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late clinical testing of cognition enhancers: demonstration of efficacy.
    Schwartz G; Bisserbe JC; Bradford D; Sennef C; Hollister L
    Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():60-2; discussion 63-4. PubMed ID: 2186415
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.